EP0773798A1 - Agent de contraste pour representation du foie - Google Patents

Agent de contraste pour representation du foie

Info

Publication number
EP0773798A1
EP0773798A1 EP95926971A EP95926971A EP0773798A1 EP 0773798 A1 EP0773798 A1 EP 0773798A1 EP 95926971 A EP95926971 A EP 95926971A EP 95926971 A EP95926971 A EP 95926971A EP 0773798 A1 EP0773798 A1 EP 0773798A1
Authority
EP
European Patent Office
Prior art keywords
compound
liver
cooh
disclosed
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95926971A
Other languages
German (de)
English (en)
Inventor
Werner Krause
Ulrich Speck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0773798A1 publication Critical patent/EP0773798A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent

Definitions

  • the invention relates to the object characterized in the claims.
  • contrast media that are not very suitable for this purpose. They are the same compounds used for uro / angiography and computed tomography. Examples of this are Amidotrizoaf » Iohexol *. Iopamidol *. Iopromide *, iopentol *. Ioversol *, Ioxaglaf » Iotrolan * and Iodixanol 9 . Tumors and metastases can only be visualized with these contrast media if they are either hyper- or hypovascularized. Lesions with the same vascular density as healthy tissue are not recognizable.
  • Water-soluble X-ray contrast media for the imaging of the liver are not known, although the need for these compounds is very high. In addition, it could be shown (W. Mützel, OH Wegener, R. Souchon, H.-J. Weinmann, in: Amiel M. (ed), Springer-Verlag, Berlin, 1982, pp. 320-3) that so far it was not possible to use water-soluble contrast agents in conventional X-ray diagnostics of the liver to be used because the saturation processes of the transport prevent a sufficiently high concentration in the liver.
  • bile contrast agents in the liver are saturable processes that competes with many other substances.
  • concentrations reached in the liver are therefore not sufficiently high for imaging in computer tomography (VG Urich, U. Speck: Biliary exeretion of contrast media. Progress in Pharmacology and Clinical Pha ⁇ nacology 8: 167-177 (1991); T. Fritzsch , W. Krause, HJ. Weinmann: Status of contrast media research in MRI, ultrasound and X-ray. Eur. Radiol. 2: 2-13 (1992)).
  • contrast media which are well tolerated, which are easy to handle pharmaceutically and are easy to use on the patient, i.e. no major interventions such as require direct application into the hepatic arteries to display the liver using a method which allows a sensitive measurement despite the lowest possible concentration of contrast medium.
  • a compound with at least one halogenated aromatic is used as a contrast medium for imaging the liver using synchrotron radiation, approximately monochromatic X-rays or X-rays below a certain wavelength.
  • compounds with at least one iodinated aromatic compound are preferably used.
  • compounds with at least one triiodinated aromatic are used.
  • synchrotron radiation which is monochromatic X-ray radiation
  • Radiation above a certain energy means radiation above the K-edge of iodine (33keV).
  • the invention is only described on the basis of synchrotron radiation.
  • the synchrotron radiation used in accordance with the invention can be, for example, high-energy monochromatic synchrotron radiation (2.5 GeV storage ring, 280 mA, 5 T Wiggler), as is e.g. at the electron synchrotron at the University of Tsukuba in Ibaraki / Japan.
  • the synchrotron radiation is in no way limited to the example described.
  • this procedure involves taking two x-rays of the liver, one without a filter and the other with a filter. After subtraction processes with an iodine filter (corresponding to the X-rays below the K-edge) and without an iodine filter (X-rays above the K-edge), an image of the ber is obtained.
  • the images can be taken at intervals of 32 msec, for example, so that the entire liver can be displayed in one pass without movement artifacts occurring.
  • the compounds used according to the invention as a contrast medium to represent the liver have the following structural features:
  • the molecular weight of the compound should be in the range of 300 to 1000 regardless of the halogen atom (s).
  • the lower limit is determined by the molecular weight that is at least necessary for hepatobiliary excretion. Furthermore, the transport mechanisms of the liver or bile also play a role for the molecular weight limits.
  • the compound should have at least one functional group with at least one negative charge, which is bound aromatically or aliphatically.
  • a preferred functional group with a negative charge is the carboxyl group. It is a carrier of a negative charge because the COOH group dissociates into COO ' and H + in aqueous medium.
  • the compound in addition to the functional group (s), each with at least one negative charge, which increases the anion transport for transfer to the liver / bile, the compound should also have lipophilic regions in the molecule which enable sufficiently high protein binding.
  • Structural features that increase lipophilicity are those atoms / groups in a molecule that do not contain oxygen or nitrogen, e.g. pure hydrocarbon residues or the iodine atom itself.
  • the hydrophilic and lipophilic areas in the compound used according to the invention should be selected such that the compound in the n-butanol / water system has a distribution coefficient P> 0.2.
  • the determination of the Distribution coefficients P are described, for example, by W. Mützel, WR. Press, H.-J. Weinmann: Physicochemical Properties and General Pha ⁇ nacology of the Nonionic Iotrolan, described in advances in the field of X-rays and nuclear medicine, Frommhold W. and Thurn P. (Ed.), Georg Thieme Verlag Stuttgart, 1989, pp. 28-32.
  • Biligrafin * (formula I) is administered intravenously in the formulation customary for cholegraphy (representation of the bile).
  • the area of the liver is scanned using synchrotron radiation.
  • the density of the healthy liver parenchyma is now also increased. Metastases are largely left out. Other lesions (hemangiomas, areas with cirrhotic changes) show typical changes in density over time after the injection. This is not the case with conventional X-rays.
  • Biliscopin * (Formula II) is slowly infused in a dose of only 2g iodine.
  • Metastases, abscesses, necroses and cysts show practically no change in density over the entire course of time, while the healthy liver parenchyma increases very rapidly, adenomas, focal nodular hyperplasias and fatty cirrhotic areas of the liver slowly increase in density.
  • Biloptin * (formula HI) is administered orally in the formulation customary for cholegraphy.
  • the area of the liver is scanned using synchrotron radiation.
  • the liver parenchyma can now be displayed. This is not the case with conventional X-rays.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne l'utilisation d'un composé renfermant au moins un composé aromatique halogéné, de préférence iodé et idéalement triiodé, en tant qu'agent de contraste pour représenter le foie au moyen d'un rayonnement synchrotron, proche de rayons X monochromatiques ou de rayons X au-dessous d'une longueur d'onde déterminée.
EP95926971A 1994-07-26 1995-07-21 Agent de contraste pour representation du foie Withdrawn EP0773798A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4426439 1994-07-26
DE4426439A DE4426439C1 (de) 1994-07-26 1994-07-26 Kontrastmittel zur Darstellung der Leber
PCT/EP1995/002902 WO1996003155A1 (fr) 1994-07-26 1995-07-21 Agent de contraste pour representation du foie

Publications (1)

Publication Number Publication Date
EP0773798A1 true EP0773798A1 (fr) 1997-05-21

Family

ID=6524172

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95926971A Withdrawn EP0773798A1 (fr) 1994-07-26 1995-07-21 Agent de contraste pour representation du foie

Country Status (7)

Country Link
EP (1) EP0773798A1 (fr)
JP (1) JPH10502936A (fr)
AU (1) AU3116395A (fr)
DE (1) DE4426439C1 (fr)
IL (1) IL114711A0 (fr)
WO (1) WO1996003155A1 (fr)
ZA (1) ZA956226B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US7194063B2 (en) 2005-02-10 2007-03-20 Brookhaven Science Associates, Llc Methods for implementing microbeam radiation therapy
US7158607B2 (en) 2005-02-10 2007-01-02 Brookhaven Science Associates, Llc Methods for assisting recovery of damaged brain and spinal cord using arrays of X-ray microplanar beams

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980885A (en) * 1974-09-06 1976-09-14 Vincent William Steward Diagnosis by proton bombardment
CH641682A5 (en) * 1978-10-05 1984-03-15 Daeniker Felix X-ray contrast medium
US4432370A (en) * 1981-10-14 1984-02-21 The Board Of Trustees Of The Leland Stanford Junior University Method and means for minimally invasive angiography using mono-chromatized synchrotron radiation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9603155A1 *

Also Published As

Publication number Publication date
IL114711A0 (en) 1995-11-27
AU3116395A (en) 1996-02-22
ZA956226B (en) 1996-03-14
DE4426439C1 (de) 1996-02-29
WO1996003155A1 (fr) 1996-02-08
JPH10502936A (ja) 1998-03-17

Similar Documents

Publication Publication Date Title
DE69229925T2 (de) Röntgenkontrastmittel zur medizinischen Bilderzeugung
DE69031946T2 (de) Perkutane lymphographie
DE102005052368B4 (de) Röntgensystem zur Erstellung diagnostischer Röntgendarstellungen unter Applikation von Kontrastmitteln
Willekens et al. Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC
DE69121562T3 (de) Kontrastmittel enthaltend einen nicht-ionischen kontrast Wirkstoff und Sodium und Kalzium Sälze
DE102005026940A1 (de) Röntgenanordnung zur Bilddarstellung eines Untersuchungsobjektes und Verwendung der Röntgenanordnung
DE2717819A1 (de) Kontrastmedium fuer roentgenlicht
DE3688799T2 (de) Biologisch abbaubare Mikrokugeln und Verfahren zu deren Herstellung.
DE69020208T2 (de) Kontrastmittel.
EP0994729B1 (fr) Utilisation d'agents de contraste intraveineux pour mammographie avec projection
EP2005970A1 (fr) Imagerie Diagnostique par combinaison de moyens de contraste
DE4426439C1 (de) Kontrastmittel zur Darstellung der Leber
Schmitz et al. Evaluation of gadobutrol in a rabbit model as a new lanthanide contrast agent for computed tomography
WO1999042139A2 (fr) Conjugues d'amidon hydroxyethyle, leur procede de production et produits pharmaceutiques les contenant
DE69717269T2 (de) T1-zeitgewichteten kernspintomogram der res-orgäne
DE60216770T2 (de) Ionisches und nicht-ionisches radiographisches kontrastmittel zur verwendung in der kombinierten roentgen- und kernspintomographiediagnostik
DE60026743T2 (de) Verwendung von Kontrastmitteln zur Herstellung eines Diagnostischen Mittels für die Darmlumenbildgebung
DE4426438A1 (de) Verwendung von Chelaten als Röntgenkontrastmittel
DE19606326A1 (de) Kontrastmittelhaltige Liposomenformulierung sowie deren Verwendung für die In-vivo-Diagnostik, insbesondere für die Darstellung des Intravasalraumes
WO1996027394A1 (fr) Utilisation de ferrites pour determiner la perfusion de tissus humains au moyen d'un diagnostic par resonance magnetique
DE102022205295B4 (de) Verfahren zur Mehrenergie-Röntgenbildgebung, Röntgeneinrichtung, Behandlungssystem, Computerprogramm und elektronisch lesbarer Datenträger
DE10118792B4 (de) Anordnung zur Aufnahme von Projektionsmammogrammen und Verwendung der Anordnung für die Projektionsmammographie
Paling Contrast dose for enhancement of computed tomograms of the brain
DE19529921C2 (de) Verwendung von MRT-Kontrastmitteln zur Ventilations-Bildgebung der Lunge
Burrows Hirnszintigraphie (einschließlich computer-ausgewertete axiale Tomographie)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19990114